MSD'S Atozet/Zeteze (ezetimibe and atorvastatin) has been granted an extension of its indications to include patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS).
The new indication was registered effective 24 May 2017.
Go to tga.gov.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 17